Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Poly(I:C)

Poly(I:C)

pharmaceutical raw materials
Poly(I:C) structure

Poly(I:C) 

structure
  • CAS No:

    24939-03-5

  • Formula:

    (C10H13N4O8P)x.(C9H14N3O8P)x

  • Chemical Name:

    Poly(I:C)

  • Synonyms:

    5′-Inosinic acid,homopolymer,complex with 5′-cytidylic acid homopolymer (1:1);5′-Inosinic acid,polymers,complex with 5′-cytidylic acid polymers (1:1);5′-Cytidylic acid,polymers,complex with 5′-inosinic acid polymers (1:1);5′-Cytidylic acid,homopolymer,complex with 5′-inosinic acid homopolymer (1:1);Poly(C).poly(I);Polyribocytidylic acid-polyriboinosinic acid complex;Poly(C:I);Polycytidylic-polyinosinic acid;Polyinosinic-polycytidylic acid complex;Polyinosinic-polycytidylic acid;Poly(rI:rC);Polyinosinic acid:polycytidylic acid;Polyinosinate:polycytidylate;Polyinosinic acid:polycytidylic acid complex;Poly(I).poly(C);Poly(rI).poly(rC);Poly(I:C);Poly(rI):poly(rC);Poly(cytidylic acid)-poly(inosinic acid);Poly(I).poly(C) complex;Poly(rI)-poly(rC);5′-Inosinic acid homopolymer-5′-cytidylic acid homopolymer complex (1:1);Polyinosinate-polycytidylate complex;NSC 120949;NSC 123233;NSC 128576;Polyinosine-polycytidylic acid;Poly(I)-poly(C);Poly I:C;104888-55-3;53539-97-2;61216-07-7

  • Categories:

    Biochemical Engineering  >  Biological Response Modifiers

Description

ChEBI: A mismatched double-stranded RNA with one strand being a polymer of inosinic acid, the other a polymer of cytidylic acid.

Poly(I:C) Basic Attributes

671.402502

671.098938

1308068-626-2

Characteristics

377.00000

-4.01670

851.4ºC at 760 mmHg

−20°C

7.7E-31mmHg at 25°C

Safety Information

3

TR0175000

Poly(I:C) Use and Manufacturing

Methods of Manufacturing

Preparation of 5'-nucleoside diphosphate pyridinium salt with 5'-nucleotide as raw material 5'-nucleotide (5'-inosinic acid or 5'-cytidine acid) [morpholine, bicyclohexylcarbodiimide Amine]→[Ethanol, 83℃]5'-nucleotide morpholine salt [tri-n-butylamine phosphate, anhydrous pyridine]→5'-nucleoside diphosphate pyridinium salt (DIP pyridine salt or CDP pyridine salt) fixation Preparation of phosphopolynucleotide phosphorylase enzyme preparation E. coli 1.683 cell → broken cell extraction → nucleic acid removal by streptotoxin precipitation → ammonium sulfate salting out → DEAE-cellulose chromatography → collection of 0.35mol/L sodium chloride for elution Preparation of the part of the solid phase carrier with the highest enzyme activity in the liquid. Agar powder is melted [toluene, carbon tetrachloride, Span-80] → After stirring and cooling, it is cross-linked with epichlorohydrin to form beads [p-β-sulfate ethyl ester] Sulfonyl aniline]→[etherification]→[sodium nitrite, hydrochloric acid]→solid phase carrier Add the separated and purified enzyme solution dropwise to the solid phase carrier in an ice bath to obtain the covalently bound immobilized polynucleotide phosphorylation Enzyme. The preparation of polyinosinic acid reduces the substrate IDP pyridine salt into sodium salt, and CDP pyridine salt into lithium salt. Enzymatic reaction, (the number of μmol/L per ml reaction solution) IDP or CDP15, Tris150, magnesium chloride 6, EDTA1, polymerase 5U, pH 9.0, 37°C, 3-4h, adjust pH 1.5-2.0 with hydrochloric acid to polymerize Creatine or polycytidylic acid is precipitated, centrifuged, and then dissolved in a phosphate buffer, and equimolar polycreatine and polycytidine are mixed to obtain polyinosine.

Uses

It has the role of immune adjuvant, which can stimulate the reticuloendothelial system, enhance the phagocytic function of phagocytes, enhance the formation of antibodies, and stimulate allograft reactions and delayed allergic reactions. It has broad-spectrum antiviral and antitumor effects. It is mainly used clinically to prevent or treat viral infections, to treat herpes zoster, herpes keratitis, and viral hepatitis. Adjuvant treatment of tumors. Adverse reactions mainly include transient hypothermia, and individual cases have high fever above 38℃, which usually subsides within 1-2 days. If the fever does not disappear within 2 days, the drug should be stopped immediately. See also fatigue, dry mouth, dizziness, nausea, etc.

Drug Function and Efficacy

No specific pharmacological effects mentioned

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • Wuzhi Weierkang Biochemical Pharmaceutical Co., Ltd.

    China China
    Active
  • Kaiping Genuine Biochemical Pharmaceutical Co., Ltd.

    China China
    Active

Recommended Suppliers of Poly(I:C)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.